top of page

SAGEIQ - The Intelligence Engine Behind Every Sage Transaction 

SAGEIQ™ is Sage Healthcare’s proprietary AI-powered research and transaction intelligence platform. It is designed to identify, qualify and prioritise the most relevant partners for every healthcare asset, technology or company.

​

Unlike generic databases or manual searches, SAGEIQ™ continuously analyses thousands of global healthcare companies, assets, pipelines, transactions and strategic priorities to determine who is most likely to transact — and on what terms.

​

What SAGEIQ™ Does

Global Target Discovery
Identifies pharmaceutical, biotech, med-tech and diagnostics companies whose portfolios, pipelines and strategic priorities align with a specific asset or technology.

 

Strategic Fit Scoring
Ranks potential partners based on therapeutic focus, modality, geographic priorities, deal history, and corporate strategy.

​

Decision-Maker Mapping
Links assets to the relevant business development and licensing executives inside each target company.

 

Deal Signal Detection
Analyses transaction history and market behaviour to identify companies actively seeking similar assets.


Why SAGEIQ™ Matters

Most healthcare deals fail not because the science is weak, but because the wrong partners are approached.

SAGEIQ™ ensures that Sage clients are presented only to companies with:

​

  • A demonstrable strategic fit

  • An active deal appetite

  • The internal capability to execute

 

This dramatically increases:

  • Probability of deal success

  • Speed to transaction

  • Quality of economic terms

 

SAGEIQ™ + Sage Professionals

SAGEIQ™ does not replace human deal-makers — it empowers them.

Our senior transaction professionals use SAGEIQ™ to:

  • Build and prioritise target shortlists

  • Drive focused engagement

  • Support negotiations with real market data

  • Maintain live “Control Sheets” tracking every deal opportunity

This creates a level of analytical rigor and execution discipline unavailable at traditional advisory firms.


The Result

Faster deals.
Better partners.
Higher value.

 

​"Deal-making success will increasingly depend on advanced analytics and AI capabilities to evaluate scientific, commercial, and competitive potential with precision.”     - PwC Global Pharma & Life Sciences Outlook

 

​

bottom of page